456
Participants
Start Date
January 31, 2007
Primary Completion Date
December 31, 2014
Study Completion Date
March 31, 2017
GP2 peptide + GM-CSF vaccine
Given intradermally every 3-4 weeks for a total of up to 6 inoculations
GM-CSF (sargramostim)
GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
AE37 + GM-CSF vaccine
Given intradermally every 3-4 weeks for a total of up to 6 inoculations
GM-CSF (sargramostim)
Given intradermally every 3-4 weeks for a total of up to 6 inoculations
Saint Savas Cancer Hospital of Athens, Athens
Sibley Memorial Hospital, Washington D.C.
Walter Reed National Military Medical Center, Bethesda
MedStar Union Memorial Hospital, Baltimore
MedStar Good Samaritan Hospital Cancer Center, Baltimore
Landstuhl Regional Medical Center, Landstuhl
STOH Clinical Research, San Antonio
University of Hawaii Cancer Center, Honolulu
Wake Forest University Comprehensive Cancer Center, Winston-Salem
Carl R. Darnall Army Medical Center, Fort Hood
San Antonio Army Medical Center, Fort Sam Houston
University of Texas MD Anderson Cancer Center, Houston
Madigan Army Medical Center - Tacoma, Tacoma
Collaborators (1)
NuGenerex Immuno-Oncology
INDUSTRY
Norwell, Inc.
INDUSTRY
San Antonio Military Medical Center
FED